Clinical trial
Targeted Therapy With Imatinib for Treatment of Poor Prognosis Mesenchymal-type Resectable Colon Cancer: a Proof-of-concept Study in the Preoperative Window Period.
NCT02685046 is registered in ClinicalTrials.gov with UMC Utrecht as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Targeted Therapy With Imatinib for Treatment of Poor Prognosis Mesenchymal-type Resectable Colon Cancer: a Proof-of-concept Study in the Preoperative Window Period.
- Lead sponsor
- UMC Utrecht
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 30, 2016
- Completion date
- September 1, 2019
- Enrollment
- 5 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.